These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 1561158)

  • 1. Drug therapy for hyperlipidemia. When reducing cardiovascular risk is a priority.
    Bays HE; Dujovne CA
    Postgrad Med; 1992 Apr; 91(5):162-4, 167-8, 171-2 passim. PubMed ID: 1561158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy: ACCORD Blood Pressure and ACCORD Lipid: how low can we go?
    Glandt M; Raz I
    Nat Rev Endocrinol; 2010 Sep; 6(9):483-4. PubMed ID: 20720591
    [No Abstract]   [Full Text] [Related]  

  • 3. Lipids and Cardiovascular Disease: Putting It All Together.
    Pownall HJ; Gotto AM
    Methodist Debakey Cardiovasc J; 2019; 15(1):5-8. PubMed ID: 31049143
    [No Abstract]   [Full Text] [Related]  

  • 4. Options for the treatment of hyperlipidemia in Type 2 diabetes mellitus and hypothyroidism: lowering the cardiovascular risk.
    Duntas L; Kolovou G
    Future Cardiol; 2011 Mar; 7(2):137-44. PubMed ID: 21453018
    [No Abstract]   [Full Text] [Related]  

  • 5. Perioperative Management of Hyperlipidemia Medications.
    Renew JR
    Curr Clin Pharmacol; 2017; 12(3):152-156. PubMed ID: 29119935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
    Blom DJ; Dent R; Castro RC; Toth PP
    Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies.
    Wei CY; Quek RGW; Villa G; Gandra SR; Forbes CA; Ryder S; Armstrong N; Deshpande S; Duffy S; Kleijnen J; Lindgren P
    Pharmacoeconomics; 2017 Mar; 35(3):297-318. PubMed ID: 27785772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders.
    Gupta S
    Vasc Health Risk Manag; 2016; 12():421-433. PubMed ID: 27877050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Currently available lipid-lowering agents.
    Levy RI
    Hosp Pract (Off Ed); 1988 Jun; 23 Suppl 1():14-21. PubMed ID: 3134381
    [No Abstract]   [Full Text] [Related]  

  • 10. Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study.
    Farnier M; Steinmetz A; Retterstøl K; Császár A
    Clin Ther; 2011 Jan; 33(1):1-12. PubMed ID: 21397769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipids in liver transplant recipients.
    Hüsing A; Kabar I; Schmidt HH
    World J Gastroenterol; 2016 Mar; 22(12):3315-24. PubMed ID: 27022213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [KLAS [Kanazawa Lipid Assessment Survey]].
    Mabuchi H; Inazu A; Higashikata T; Nohara A; Koizumi J
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():469-76. PubMed ID: 11347115
    [No Abstract]   [Full Text] [Related]  

  • 13. More Nuanced Guidelines for Lipid Lowering to Prevent CVD.
    Shaughnessy AF
    Am Fam Physician; 2016 Jan; 93(1):59. PubMed ID: 26760843
    [No Abstract]   [Full Text] [Related]  

  • 14. [Nutraceuticals: a useful tool for cardiologists to improve lipid profile?].
    Covolo E; Bilato C
    G Ital Cardiol (Rome); 2018 Feb; 19(2):81-90. PubMed ID: 29531380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia.
    Farnier M
    Expert Rev Cardiovasc Ther; 2012 May; 10(5):565-75. PubMed ID: 22651832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bimonthly update: lipidology. Hyperlipidaemia and cardiovascular disease.
    Sussekov AV; Stekolschikova OD
    Curr Opin Lipidol; 2000 Oct; 11(5):559-62. PubMed ID: 11048899
    [No Abstract]   [Full Text] [Related]  

  • 17. New drugs for reducing cardiovascular risk in women.
    Thacker HL; Saadi H
    Cleve Clin J Med; 1997 Oct; 64(9):493-502. PubMed ID: 9339048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed drug combination in hypertension and hyperlipidaemia in the developing world.
    Seedat YK
    Cardiovasc J Afr; 2008; 19(3):124-6. PubMed ID: 18568170
    [No Abstract]   [Full Text] [Related]  

  • 19. Hyperlipidemia. What to do when life-style changes aren't enough.
    Peters WL
    Postgrad Med; 1991 Oct; 90(5):213-7, 220-4. PubMed ID: 1924009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of hyperlipidemia in older adults.
    Alexander KP; Blazing MA; Rosenson RS; Hazard E; Aronow WS; Smith SC; Ohman EM
    J Cardiovasc Pharmacol Ther; 2009 Mar; 14(1):49-58. PubMed ID: 19124599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.